

# Anita Riecher-Rössler

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/651591/publications.pdf](https://exaly.com/author-pdf/651591/publications.pdf)

Version: 2024-02-01

250  
papers

15,895  
citations

29928

54  
h-index

20222

117  
g-index

297  
all docs

297  
docs citations

297  
times ranked

15885  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. <i>Schizophrenia Bulletin</i> , 2024, 50, 579-588.	4.6	1
2	Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis. <i>European Psychiatry</i> , 2023, 66, .	0.2	1
3	Influence of cannabis use on incidence of psychosis in people at clinical high risk. <i>Psychiatry and Clinical Neurosciences</i> , 2023, 77, 469-477.	2.3	4
4	Probing the communication patterns of different chondrocyte subtypes in osteoarthritis at the single cell level using pattern recognition and manifold learning. <i>Scientific Reports</i> , 2023, 13, .	3.4	0
5	The role of gender as a barrier to the professional development of psychiatrists. <i>European Psychiatry</i> , 2023, 66, .	0.2	2
6	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. <i>Psychological Medicine</i> , 2022, 52, 1569-1577.	5.2	14
7	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 100-110.	4.6	13
8	Novel Gyrfication Networks Reveal Links with Psychiatric Risk Factors in Early Illness. <i>Cerebral Cortex</i> , 2022, 32, 1625-1636.	3.2	2
9	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. <i>Schizophrenia Research: Cognition</i> , 2022, 28, 100222.	1.3	11
10	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 147-156.	6.3	4
11	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	4
12	Editorial: Women and the Pandemic. <i>Archives of Women's Mental Health</i> , 2022, 25, 255.	2.8	1
13	Machine learning based prediction and the influence of complement " Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 50-60.	6.3	5
14	Editorial: Sex and the Suffering Brain - A Call for Sex-Stratified Analyses in Psychiatric Research. <i>Frontiers in Psychiatry</i> , 2022, 13, 849009.	2.7	3
15	Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. <i>Biological Psychiatry</i> , 2022, 92, 552-562.	1.3	19
16	Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. <i>Scientific Reports</i> , 2022, 12, 6652.	3.4	4
17	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. <i>JAMA Psychiatry</i> , 2022, 79, 677.	11.4	9
18	Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. <i>Translational Psychiatry</i> , 2022, 12, .	4.9	7

#	ARTICLE	IF	CITATIONS
19	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. <i>Molecular Psychiatry</i> , 2021, 26, 2590-2604.	8.2	17
20	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 874-881.	1.9	10
21	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , 2021, 230, 104-107.	2.1	6
22	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021, 15, 642-651.	1.9	13
23	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. <i>Biological Psychiatry</i> , 2021, 89, 288-297.	1.3	53
24	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. <i>JAMA Psychiatry</i> , 2021, 78, 77.	11.4	62
25	The Augmented Classical Twin Design: Incorporating Genome-Wide Identity by Descent Sharing Into Twin Studies in Order to Model Violations of the Equal Environments Assumption. <i>Behavior Genetics</i> , 2021, 51, 223-236.	2.0	7
26	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. <i>JAMA Psychiatry</i> , 2021, 78, 195.	11.4	146
27	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. <i>Schizophrenia Bulletin</i> , 2021, 47, 1018-1028.	4.6	11
28	Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis. <i>Journal of Psychiatric Research</i> , 2021, 136, 428-434.	3.2	19
29	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. <i>Translational Psychiatry</i> , 2021, 11, 312.	4.9	9
30	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. <i>ELife</i> , 2021, 10, .	5.9	7
31	Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study. <i>Schizophrenia Research</i> , 2021, 236, 48-53.	2.1	6
32	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.4	5
33	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	8.2	28
34	Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. <i>Schizophrenia Bulletin</i> , 2021, 47, 849-863.	4.6	21
35	Quantum dynamics simulation of intramolecular singlet fission in covalently linked tetracene dimer. <i>Journal of Chemical Physics</i> , 2021, 155, 194101.	3.1	18
36	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	1.3	52

#	ARTICLE	IF	CITATIONS
37	An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. <i>Psychological Medicine</i> , 2020, 50, 2034-2045.	5.2	23
38	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	2.1	10
39	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <i>Schizophrenia Research</i> , 2020, 226, 44-51.	2.1	30
40	Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 539-548.	3.4	13
41	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 190.	11.4	25
42	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.3	16
43	T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES. <i>Schizophrenia Bulletin</i> , 2020, 46, S238-S239.	4.6	0
44	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2020, 46, S244-S245.	4.6	0
45	EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients. <i>Frontiers in Psychiatry</i> , 2020, 11, 600606.	2.7	16
46	From Speech Illusions to Onset of Psychotic Disorder: Applying Network Analysis to an Experimental Measure of Aberrant Experiences. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	4
47	EEG microstates as biomarker for psychosis in ultra-high-risk patients. <i>Translational Psychiatry</i> , 2020, 10, 300.	4.9	59
48	Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. <i>Translational Psychiatry</i> , 2020, 10, 303.	4.9	75
49	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. <i>Schizophrenia Bulletin</i> , 2020, 46, S104-S104.	4.6	0
50	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 48-54.	2.1	9
51	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene-Environment Interactions study. <i>European Psychiatry</i> , 2020, 63, e25.	0.2	15
52	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2020, 46, 823-833.	4.6	16
53	Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2020, 218, 267-275.	2.1	28
54	Menopause and Mental Health. <i>Mental Health and Illness Worldwide</i> , 2020, , 147-173.	0.0	5

#	ARTICLE	IF	CITATIONS
55	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 552175.	2.7	5
56	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in at-risk mental state and first episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 853-858.	1.9	11
57	Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 969-976.	1.9	7
58	Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 545-554.	2.7	39
59	Vulnerability and Protective Factors for Mental Health: A Rereading in Gender Perspective. , 2019, , 25-36.		1
60	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. <i>Schizophrenia Bulletin</i> , 2019, 46, 252-260.	4.6	13
61	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 393.	2.7	24
62	Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis. <i>European Psychiatry</i> , 2019, 62, 30-37.	0.2	26
63	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 345.	2.7	30
64	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. <i>Scientific Reports</i> , 2019, 9, 8516.	3.4	11
65	Effect of cantilevers' dimensions on phase contrast in multifrequency atomic force microscopy. <i>Microscopy Research and Technique</i> , 2019, 82, 1438-1447.	2.3	5
66	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. <i>European Psychiatry</i> , 2019, 59, 52-59.	0.2	20
67	No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis. <i>European Journal of Neuroscience</i> , 2019, 50, 3060-3071.	3.5	3
68	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. <i>Microbial Biotechnology</i> , 2019, 13, 1283-1288.	1.9	7
69	Estrogens and SERMS as adjunctive treatments for schizophrenia. <i>Frontiers in Neuroendocrinology</i> , 2019, 53, 100743.	5.2	48
70	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. <i>Schizophrenia Bulletin</i> , 2019, 45, S177-S178.	4.6	0
71	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019, 206, 67-74.	2.1	52
72	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Bride price payment and women's autonomy: Findings from qualitative interviews from Nigeria. <i>Women and Health</i> , 2019, 59, 775-788.	1.1	6
74	WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 17-50.	2.7	32
75	Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review. <i>Schizophrenia Research</i> , 2019, 210, 39-47.	2.1	70
76	Individualized prediction of psychosis in subjects with an at-risk mental state. <i>Schizophrenia Research</i> , 2019, 214, 18-23.	2.1	27
77	Gender differences in first self-perceived signs and symptoms in patients with an at-risk mental state and first episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 582-588.	1.9	24
78	Menopause and Mental Health. <i>Mental Health and Illness Worldwide</i> , 2019, , 1-27.	0.0	0
79	Disorganized Gyrfication Network Properties During the Transition to Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 613.	11.4	57
80	Sexually dimorphic subcortical brain volumes in emerging psychosis. <i>Schizophrenia Research</i> , 2018, 199, 257-265.	2.1	12
81	Clinical trajectories in the ultra-high risk for psychosis population. <i>Schizophrenia Research</i> , 2018, 197, 550-556.	2.1	56
82	The Frankfurt Complaint Questionnaire for self-assessment of basic symptoms in the early detection of psychosis: Factor structure, reliability, and predictive validity. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1600.	2.3	7
83	Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)? <i>European Psychiatry</i> , 2018, 52, 38-44.	0.2	9
84	Early detection of psychosis: helpful or stigmatizing experience? A qualitative study. <i>Microbial Biotechnology</i> , 2018, 12, 66-73.	1.9	23
85	Outcome of individuals not at risk of psychosis and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP). <i>Microbial Biotechnology</i> , 2018, 12, 907-914.	1.9	4
86	Abnormal brain connectivity during error-monitoring in the psychosis high-risk state. <i>Schizophrenia Research</i> , 2018, 193, 261-262.	2.1	1
87	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. <i>Schizophrenia Bulletin</i> , 2018, 44, S132-S133.	4.6	5
88	T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S116-S116.	4.6	2
89	T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S199-S199.	4.6	0
90	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S228-S228.	4.6	1

#	ARTICLE	IF	CITATIONS
91	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. Schizophrenia Bulletin, 2018, 44, S378-S379.	4.6	1
92	Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis. Scientific Reports, 2018, 8, 16516.	3.4	1
93	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. JAMA Psychiatry, 2018, 75, 1156.	11.4	268
94	New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages. PLoS Genetics, 2018, 14, e1007282.	3.4	62
95	The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. Psychology Research and Behavior Management, 2018, Volume 11, 157-168.	2.9	8
96	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2018, 44, S99-S99.	4.6	1
97	Sex and gender differences in schizophrenic psychoses—a critical review. Archives of Women's Mental Health, 2018, 21, 627-648.	2.8	151
98	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	699
99	The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis. Psychiatry Research, 2018, 268, 21-27.	3.4	24
100	Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling. PLoS ONE, 2018, 13, e0196936.	2.5	3
101	Patient-Identified Priorities Leading to Attempted Suicide. Crisis, 2018, 39, 37-46.	1.5	5
102	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2017, 43, sbw110.	4.6	40
103	NEURAPRO—study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Microbial Biotechnology, 2017, 11, 418-428.	1.9	55
104	Correlations between self-reporting and observer-reporting of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender. Microbial Biotechnology, 2017, 11, 461-470.	1.9	13
105	Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophrenia Research, 2017, 189, 111-116.	2.1	40
106	Sex and gender differences in mental disorders. Lancet Psychiatry, the, 2017, 4, 8-9.	7.6	366
107	Effect of $\omega$ -3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. JAMA Psychiatry, 2017, 74, 19.	11.4	223
108	Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state. Biological Psychology, 2017, 126, 12-18.	2.3	1

#	ARTICLE	IF	CITATIONS
109	Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells. <i>Gene</i> , 2017, 614, 65-73.	2.3	28
110	Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. <i>Lancet Psychiatry</i> , 2017, 4, 63-72.	7.6	119
111	Duration of untreated psychosis/illness and brain volume changes in early psychosis. <i>Psychiatry Research</i> , 2017, 255, 332-337.	3.4	25
112	Prediction of conversion to psychosis in individuals with an at-risk mental state. <i>Current Opinion in Psychiatry</i> , 2017, 30, 209-219.	6.6	50
113	Depression in der Peripartalzeit – Diagnostik, Therapie und Prophylaxe. <i>Frauenheilkunde Update</i> , 2017, 10, 531-545.	0.0	0
114	Age-related brain structural alterations as an intermediate phenotype of psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 307-319.	2.8	34
115	Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences. <i>Frontiers in Psychiatry</i> , 2017, 8, 115.	2.7	23
116	Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients. <i>Frontiers in Psychiatry</i> , 2017, 8, 206.	2.7	6
117	Education and Reproductive Autonomy: The Case of Married Nigerian Women. <i>Narrative Inquiry in Bioethics</i> , 2017, 7, 231-244.	0.1	8
118	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. <i>Lecture Notes in Computer Science</i> , 2017, 10541, 371-378.	1.0	4
119	Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms. <i>Frontiers in Psychiatry</i> , 2016, 7, 189.	2.7	15
120	Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. <i>NPJ Schizophrenia</i> , 2016, 2, 16033.	4.5	46
121	The role of vulnerability factors in individuals with an at-risk mental state of psychosis. <i>Neuropsychiatrie</i> , 2016, 30, 18-26.	2.1	4
122	Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms. <i>Schizophrenia Research</i> , 2016, 175, 20-26.	2.1	16
123	High time for a paradigm shift in psychiatry. <i>World Psychiatry</i> , 2016, 15, 131-133.	9.6	7
124	Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study. <i>World Psychiatry</i> , 2016, 15, 146-154.	9.6	33
125	Pourquoi et comment soigner plus précisément les troubles psychotiques? <i>Presse Medicale</i> , 2016, 45, 992-1000.	2.1	5
126	Der Einfluss eines elektronischen Erinnerungssystems auf die leitlinientreue Behandlung von psychotischen Erkrankungen. <i>Neuropsychiatrie</i> , 2016, 30, 191-197.	2.1	3



#	ARTICLE	IF	CITATIONS
127	CuSCN as selective contact in solution-processed small-molecule organic solar cells leads to over 7% efficient porphyrin-based device. <i>Journal of Materials Chemistry A</i> , 2016, 4, 11009-11022.	10.5	39
128	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 732-743.	4.6	186
129	Neural oscillations in antipsychotic-naïve patients with a first psychotic episode. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 296-307.	2.7	12
130	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. <i>JAMA Psychiatry</i> , 2016, 73, 113.	11.4	367
131	Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 285-295.	2.7	43
132	Weibliche Rollen und psychische Gesundheit. , 2016, , 19-34.		6
133	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 367-376.	2.8	37
134	Appropriateness of Care and Joint Decision-Making Strategies. , 2016, , 207-209.		0
135	At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. <i>World Psychiatry</i> , 2015, 14, 322-332.	9.6	212
136	Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing. <i>NeuroImage: Clinical</i> , 2015, 9, 555-563.	2.8	21
137	Orbitofrontal response to drug-related stimuli after heroin administration. <i>Addiction Biology</i> , 2015, 20, 570-579.	2.7	34
138	Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity. <i>Brain</i> , 2015, 138, 217-228.	8.0	23
139	Modulation of motivational salience processing during the early stages of psychosis. <i>Schizophrenia Research</i> , 2015, 166, 17-23.	2.1	47
140	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. <i>Brain</i> , 2015, 138, 2059-2073.	8.0	135
141	Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. <i>CNS Spectrums</i> , 2015, 20, 122-129.	1.3	10
142	Super proton/electron mixed conduction in graphene oxide hybrids by intercalating sulfate ions. <i>Journal of Materials Chemistry A</i> , 2015, 3, 20892-20895.	10.5	31
143	Depression in der Peripartalzeit – Diagnostik, Therapie und Prophylaxe. <i>PSYCH Up2date</i> , 2015, 9, 149-160.	0.2	0
144	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. <i>NeuroImage: Clinical</i> , 2015, 8, 230-237.	2.8	13

#	ARTICLE	IF	CITATIONS
145	Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 919-929.	4.6	60
146	Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers. <i>Schizophrenia Bulletin</i> , 2015, 41, 471-482.	4.6	144
147	Perinatal mental health service provision in Switzerland and in the UK. <i>Swiss Medical Weekly</i> , 2015, 145, w14011.	1.5	7
148	FrÃ¼herkennung und FrÃ¼hintervention bei beginnenden Psychosen. <i>Neurotransmitter</i> , 2015, 26, 50-54.	0.0	0
149	Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments. <i>Swiss Medical Weekly</i> , 2015, 145, w14099.	1.5	5
150	Single- and multiple-dose pharmacokinetics of arginase inhibitor N <sup>1</sup> -hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats. <i>General Physiology and Biophysics</i> , 2014, 33, 189-198.	0.9	15
151	Altered prefrontal connectivity after acute heroin administration during cognitive control. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1375-1385.	2.1	16
152	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	4.6	235
153	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 239-248.	2.8	41
154	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. <i>Schizophrenia Bulletin</i> , 2014, 40, 1140-1153.	4.6	389
155	Evidence for an agitated/aggressive syndrome predating the onset of psychosis. <i>Schizophrenia Research</i> , 2014, 157, 26-32.	2.1	20
156	Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses. <i>Biological Psychiatry</i> , 2014, 76, 289-296.	1.3	113
157	Help-seeking and pathways to care in the early stages of psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1033-1043.	3.4	63
158	Acute effects of heroin on emotions in heroin-dependent patients. <i>American Journal on Addictions</i> , 2013, 22, 598-604.	1.9	36
159	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. <i>Psychiatry Research</i> , 2013, 209, 266-272.	3.4	115
160	Sollen junge Menschen mit Psychoserisikosyndrom behandelt werden?. <i>Neuropsychiatrie</i> , 2013, 27, 153-156.	2.1	0
161	Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 102-108.	1.9	28
162	Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?. <i>Psychiatry Research</i> , 2013, 210, 427-431.	3.4	17

#	ARTICLE	IF	CITATIONS
163	The attenuated psychosis syndrome in DSM-5. Schizophrenia Research, 2013, 151, 295.	2.1	5
164	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.4	1,256
165	Duration of untreated psychosis and cognitive functioning. Schizophrenia Research, 2013, 145, 43-49.	2.1	31
166	Can cognitive deficits facilitate differential diagnosis between atâ€risk mental state for psychosis and depressive disorders?. Microbial Biotechnology, 2013, 7, 381-390.	1.9	17
167	Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study. Frontiers in Psychiatry, 2013, 4, 135.	2.7	27
168	Brain Connectivity Abnormalities Predating the Onset of Psychosis. JAMA Psychiatry, 2013, 70, 903.	11.4	94
169	Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition. Schizophrenia Bulletin, 2013, 39, 1105-1114.	4.6	66
170	Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response. Journal of Clinical Psychopharmacology, 2013, 33, 193-198.	1.4	35
171	Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control. Neuropsychopharmacology, 2013, 38, 2231-2239.	5.6	52
172	Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. Schizophrenia Bulletin, 2012, 38, 1234-1246.	4.6	142
173	Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?. Current Pharmaceutical Design, 2012, 18, 416-421.	1.9	13
174	Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study. Schizophrenia Research, 2012, 142, 217-222.	2.1	52
175	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	4.6	85
176	Different duration of atâ€risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. Human Brain Mapping, 2012, 33, 2281-2294.	3.7	64
177	First selfâ€perceived signs and symptoms in emerging psychosis compared with depression. Microbial Biotechnology, 2012, 6, 455-459.	1.9	3
178	Cingulate Volume Abnormalities in Emerging Psychosis. Current Pharmaceutical Design, 2012, 18, 495-504.	1.9	21
179	Cost of attempted suicide: a retrospective study of extent and associated factors. Swiss Medical Weekly, 2012, 142, w13648.	1.5	29
180	Pituitary volume increase during emerging psychosis. Schizophrenia Research, 2011, 125, 41-48.	2.1	57

#	ARTICLE	IF	CITATIONS
181	Depression und Psychose in der Menopause - kann eine Hormontherapie hilfreich sein?. <i>Psychiatrie Und Psychotherapie</i> , 2011, 7, 129-134.	0.1	0
182	Neuroanatomical Abnormalities That Predate the Onset of Psychosis. <i>Archives of General Psychiatry</i> , 2011, 68, 489.	13.2	230
183	A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 986-993.	2.3	200
184	Pan-azole-Resistant <i>Candida guilliermondii</i> from a Leukemia Patient's Silent Funguria. <i>Mycopathologia</i> , 2010, 169, 457-459.	3.0	19
185	Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. <i>Journal of Psychiatric Research</i> , 2010, 44, 447-453.	3.2	82
186	The Self-screen-Prodrome as a short screening tool for pre-psychotic states. <i>Schizophrenia Research</i> , 2010, 123, 217-224.	2.1	31
187	EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. <i>Schizophrenia Research</i> , 2010, 123, 208-216.	2.1	42
188	Neural effects of heroin - Relation to anxiety stress. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 816-817.	5.0	2
189	Hyperprolactinaemia in early psychosis - not only due to antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1342-1344.	5.0	75
190	Veblen on the machine process and technological change. <i>Cambridge Journal of Economics</i> , 2010, 34, 601-615.	1.4	20
191	Estrogens and Gonadal Function in Schizophrenia and Related Psychoses. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 8, 155-171.	0.0	64
192	Depression in der Schwangerschaft. <i>Therapeutische Umschau Revue Therapeutique</i> , 2010, 67, 571-575.	0.1	4
193	Domestic violence against women: Definitions, epidemiology, risk factors and consequences. <i>Swiss Medical Weekly</i> , 2010, 140, w13099.	1.5	70
194	Depression in der frühen Mutterschaft. <i>Therapeutische Umschau Revue Therapeutique</i> , 2010, 67, 576-580.	0.1	0
195	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009, 166, 675-682.	8.7	293
196	Elternschaft und Belastungserleben: Psychometrische Überprüfung des Parenting-Stress-Index (PSI) an einer deutschsprachigen Stichprobe. <i>PPmP Psychotherapie Psychosomatik Medizinische Psychologie</i> , 2009, 59, 224-233.	0.4	15
197	EEG: a helpful tool in the prediction of psychosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 257-262.	3.4	27
198	Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up. <i>Biological Psychiatry</i> , 2009, 66, 1023-1030.	1.3	245

#	ARTICLE	IF	CITATIONS
199	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. Schizophrenia Research, 2009, 113, 109-110.	2.1	14
200	Negative symptoms in neuroleptic-naïve patients with first-episode psychosis correlate with QEEG parameters. Schizophrenia Research, 2009, 115, 231-236.	2.1	22
201	Intervention in Individuals at Ultra-High Risk for Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1206-1212.	2.3	261
202	Insular pathology in the at-risk mental state. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 254-255.	3.4	4
203	Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophrenia Research, 2008, 106, 108-114.	2.1	211
204	Anterior cingulate pathology in the prodromal stage of schizophrenia. NeuroImage, 2008, 39, 553-554.	4.4	34
205	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, The, 2008, 371, 1085-1097.	12.1	980
206	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. International Journal of Neuropsychopharmacology, 2007, 10, S1-207.	2.1	56
207	Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. British Journal of Psychiatry, 2007, 191, s69-s75.	3.6	131
208	Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis. European Psychiatry, 2007, 22, 264-264.	0.2	8
209	Psychotic experiences in the general population: A twenty-year prospective community study. Schizophrenia Research, 2007, 92, 1-14.	2.1	267
210	Neuropsychological deficits in individuals with an at risk mental state for psychosis – Working memory as a potential trait marker. Schizophrenia Research, 2007, 97, 14-24.	2.1	88
211	Regional Gray Matter Volume Abnormalities in the At Risk Mental State. Biological Psychiatry, 2007, 61, 1148-1156.	1.3	298
212	Früherkennung schizophrener Psychosen bei Männern und Frauen. Therapeutische Umschau Revue Therapeutique, 2007, 64, 337-343.	0.1	4
213	Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. International Journal of Psychiatry in Clinical Practice, 2006, 10, 174-181.	2.7	5
214	High-transmission hybrid-effect-assisted nanoaperture. Optics Letters, 2006, 31, 655.	3.3	11
215	Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 201-206.	3.4	46
216	Werden psychisch Kranke zu schnell in die Rente –abgeschoben–?. Psychiatrische Praxis, 2005, 32, 172-176.	0.5	13

#	ARTICLE	IF	CITATIONS
217	Size of burden of schizophrenia and psychotic disorders. <i>European Neuropsychopharmacology</i> , 2005, 15, 399-409.	1.6	524
218	Estrogens and Schizophrenia. , 2005, , 31-52.		21
219	Role of fO2 on fluid saturation in oceanic basalt (reply). <i>Nature</i> , 2004, 430, 1-2.	36.2	1
220	Oestrogens and schizophrenia. <i>Current Opinion in Psychiatry</i> , 2003, 16, 187-192.	6.6	26
221	Late-Onset Schizophrenia Versus Paranoid Psychoses. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 595-604.	1.1	5
222	Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 595-604.	1.1	15
223	Ä–strogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und GynÄkologie. <i>Geburtshilfe Und Frauenheilkunde</i> , 2002, 62, 429-435.	0.4	2
224	The gene family coding for the light-harvesting polypeptides of Photosystem I of the red alga <i>Galdieria sulphuraria</i> . <i>Photosynthesis Research</i> , 2001, 68, 121-130.	2.9	18
225	Psychische Erkrankungen bei Frauen - einige Argumente fÄ¼r eine geschlechtersensible Psychiatrie und Psychotherapie/ Mental diseases in women - some arguments for a gender-sensitive psychiatry and psychotherapy. <i>Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie</i> , 2000, 46, 129-139.	0.9	13
226	Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia. , 1999, , 249-258.		0
227	Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. <i>Nature Medicine</i> , 1998, 4, 713-717.	30.1	1,057
228	Theory of natural circular dichroism in x-ray Raman scattering from molecules. <i>Physical Review A</i> , 1997, 55, 2716-2722.	2.5	5
229	Psychische StÄ¼rungen und Erkrankungen nach der Entbindung. <i>Fortschritte Der Neurologie Psychiatrie</i> , 1997, 65, 97-107.	0.2	31
230	What do we really know about late-onset schizophrenia?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1997, 247, 195-208.	3.4	62
231	50 Jahre nach Manfred Bleuler. <i>Der Nervenarzt</i> , 1997, 68, 159-170.	0.8	9
232	Changing patterns of mental health care in Germany. <i>International Journal of Law and Psychiatry</i> , 1996, 19, 391-411.	0.9	8
233	Further evidence for a specific role of estradiol in schizophrenia?. <i>Biological Psychiatry</i> , 1994, 36, 492-494.	1.3	97
234	Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. <i>Biological Psychiatry</i> , 1994, 36, 137-139.	1.3	97

#	ARTICLE	IF	CITATIONS
235	Wirken Å–strogene antipsychotisch?. Fortschritte Der Neurologie Psychiatrie, 1994, 62, 22-28.	0.2	7
236	Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany. Psychiatric Services, 1994, 45, 818-822.	2.2	9
237	Quantitative genetics of life-history and morphology in a rare plant, Senecio integrifolius. Heredity, 1993, 70, 503-514.	2.7	54
238	Schizophrenia and oestrogens â€” is there an association?. European Archives of Psychiatry and Clinical Neuroscience, 1993, 242, 323-328.	3.4	144
239	The Influence of Age and Sex on the Onset and Early Course of Schizophrenia. British Journal of Psychiatry, 1993, 162, 80-86.	3.6	601
240	Die Zwangseinweisung psychiatrischer Patienten im nationalen und internationalen Vergleich - HÄufigkeiten und EinfluÅfaktoren. Fortschritte Der Neurologie Psychiatrie, 1992, 60, 375-382.	0.2	18
241	Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. Schizophrenia Research, 1992, 6, 114-115.	2.1	20
242	First onset and early symptomatology of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 109-118.	3.4	182
243	Is age of onset in schizophrenia influenced by marital status?. Social Psychiatry and Psychiatric Epidemiology, 1992, 27, 122-128.	3.4	40
244	Are all quantum measurements reducible to local position measurements?. Journal of Physics A, 1991, 24, L425-L430.	1.6	5
245	Pau Hana: Plantation Life and Labor in Hawaii. By Ronald Takaki. Honolulu: University of Hawaii Press, 1983. Pp. xiv, 213. \$15.00.. Journal of Economic History, 1984, 44, 891-892.	1.4	0
246	Increased Symptom Consolidation Preceding Transition to Psychosis: A Phenomenological Network Study. SSRN Electronic Journal, 0, , .	0.3	1
247	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youth at Ultra-High Risk for Psychosis. SSRN Electronic Journal, 0, , .	0.3	0
248	Professional Conduct and Handling Misconduct in Psychotherapy: Ethical Practice between Boundaries, Relationships, and Reality. , 0, , 1001-1018.		1
249	The relationship between grey matter volume and clinical and functional outcomes in people at clinical high risk for psychosis. Schizophrenia Bulletin Open, 0, , .	1.7	2
250	Do Cognitive Subtypes Exist in People at Clinical High Risk for Psychosis? Results From the EU-GEI Study. Schizophrenia Bulletin, 0, , .	4.6	0